CTOs on the Move

Detroit Wayne Mental Health Authority

www.dwihn.org

 
DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dwihn.org
  • 707, West Milwaukee Avenue
    Detroit, MI USA 48202
  • Phone: 313.344.9099

Executives

Name Title Contact Details

Similar Companies

Medac Corporation

Medac Corporation is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

International Medication Systems

International Medication Systems is a South El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cadila Pharmaceuticals - CPL

Cadila Pharmaceuticals - CPL, Inc. is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TBS Dental

We create premium products to make dentistry more efficient. Over the years, TBS has designed and developed a number of contemporary, state-of-the-art instruments with the intent of modernization.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.